

KEY DATA

Net Sales Q4 2018 grew +8.3% year on year

Gross Margin Q4 2018 closed at 64.3%, a 200 bps year-on-year improvement

EBITDA margin for the three months of Q4 2018 closed at 18.6%

Free Cash Flow of Ps. 1.37 billion⁽¹⁾ for the twelve months of 2018

Capex Investments for the twelve months of 2018 reached Ps. 1.23 billion allocated to: - New Plant -Brand acquisitions

> Ps. 134.0 million invested in Share Buy-backs in 2018.

Key Metrics	Q4'17 Q4'18
Cash Conversion Cycle	97 82
Net Debt / EBITDA	1.39 1.87

(1) Excluding investments in the manufacturing facility and brands acquisitions.

Genomma Lab Internacional Reports Restatement of Fourth Quarter & Full Year 2018 Results

Mexico City, May 1, 2019 – Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma Lab" or "the Company"), today announced its results for the fourth quarter and full year ended December 31, 2018. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with International Financial Reporting Standards (IFRS). These figures include the effects of the adoption of hyperinflation accounting (IAS 29 & IAS 21).

The following table provides an abridged Income Statement, in millions of Mexican pesos. The margin for each figure represents its ratio to net sales and the percentage change in the fourth quarter 2018 as compared with the same period in 2017:

	Q4-2017 As Reported	% Sales	Q4-2018 As Reported	IAS 21 & 29	Q4-2018 ⁽²⁾ Re-stated	% Sales
Net Sales	2,885.2	100.0%	3,136.4	(12.3)	3,124.1	100.0%
Gross Profit	1,798.0	62.3%	2,012.9	(5.6)	2,007.3	64.3%
Operating Income	595.9	20.7%	550.6	+1.4	552.0	17.7%
EBITDA ⁽³⁾	613.2	21.3%	579.3	+1.4	580.7	18.6%
Net Income ⁽⁴⁾	338.6	11.7%	327.0	(121.2)	205.8	6.6%

(2) 2018 Restated Results by the application of IAS-29 & IAS-21 under IFRS standards as if adopted on January 1st. 2018.
(3) EBITDA is defined as operating income before depreciation and amortization.
(4) Net Income of Majority Shareholders for 2017.

NOTE: These results incorporate the impact of the International Accounting Standard IAS-29 (hyperinflationary accounting) and major currency devaluation of the Argentinean peso detailed on page 8.

Comments from the CEO

Mr. Jorge Brake, Chief Executive Officer, commented: "2018 was an important year for Genomma Lab. We successfully completed the turnaround process we embarked upon in 2015 streamlining our business model while leveraging Genomma's efficient operating structure and strong go-to market and marketing capabilities. We also completed the final phase of our cost containment and cash generation program, resulting in a solid foundation which will enable us to take advantage of the exciting opportunities that lie ahead."

Mr. Brake continued: "Despite a major currency devaluation impact in our second largest market and other one-time effects, Q4 results were positive both from a topline perspective and operationally. Our team managed to overcome in this challenging environment. I'm confident that today our Company is well positioned to turn our focus to growth and innovation, with improved performance as we continue to leverage our deep understanding of Genomma's customers, consumers and categories while delivering brand-accretive marketing to expand our business base."



KEY DATA Q4-2018

Business Review

% Sales by Segment:



Genomma Lab reported an +8.3% year on year increase in the topline for the fourth quarter 2018 reflecting strong topline performance in Argentina, U.S.A., Brazil, Colombia and Central America operations.

The Ps. 238.9 million increase was driven by key innovation initiatives, and a strategy of perfect store execution that enhanced visibility at the point of sale in the international subsidiaries, as well as the application of IAS-29 (hyperinflationary accounting in Argentina). On the other hand, topline and EBITDA were negatively impacted by major currency translation from Argentinean pesos on Genomma's financial results.

EBITDA margin for the quarter reached 18.6% to close at Ps. 580.7 million. During the quarter, the Company executed stronger TV campaigns and trade marketing activities to drive topline growth and incurred pre-operating expenses associated with the new manufacturing facility, one-off expenses from relocating warehouse logistics at the Company's US operation, and CEO transition-related expenses.

The Company also recorded a net positive result of Ps. 83.3 million in the "Other (income) expenses" line, related to extraordinary proceeds obtained from Genomma's distribution capabilities in Latin America, and the net effect from the sale of a non-core asset in Brazil including its one-off charge that had no cash impact.

Mexico

While sell-in figures during the fourth quarter increased by 1.2%, year on year, sellout, a proxy measure of consumer demand, expanded by 7.6% during this period. The difference between sell-out and sell-in is a result of the Company's prudent inventory management at the trade.

The sales mix for the quarter fostered growth in the OTC category. The *Medicasp*[®], *Tukol*[®] and *Alliviax*[®] brands were actively marketed with a new communication strategy, resulting in double-digit growth in sell-out during the seasonal campaign.

EBITDA for the quarter reached Ps. 173.9 million; a 14.7% margin reflecting a 4.0 percentage point year on year contraction. EBITDA was impacted by increased investments in TV and trade advertising, as well as pre-operating expenses from Genomma's new manufacturing facility, in addition to a one-time effect related to the CEO transition.

During the quarter, the Company invested Ps. 389.2 million in the new manufacturing facility and incurred pre-operating and pre-production expenses in the amount of Ps. 30.3 million. Furthermore, in order to track performance and ensure accountability of every line of business, the assets of the new OTC and PC plants are being transferred





to wholly-owned subsidiaries, both of which are separate and independent from the existing commercial entities.

The construction phase of the OTC manufacturing facility was concluded during the quarter. As of today, the Company is going through the authorization process to obtain the sanitary license for the solids production line, once it is granted, the Company will seek to obtain from the authorities the GMPs (*Good Manufacturing Practices*) to begin operations.

Subsequently, additional production capability for semi-solids and liquids will be added, requiring additional government authorizations. Genomma's Personal Care manufacturing facility is under construction and expected to be completed during the second half of 2019.

U.S.

During the fourth quarter 2018, Genomma's U.S. operations continued its successful transformation process to drive topline growth. Net sales increased by 18.9% in Mexican pesos and +13.7% in local currency. New product launches including *Tukol Sugar Free*[®], *Tukol DM Max*[®], *Goicoechea Diabet-TX*[®], *Tío Nacho Ginseng*[®] and *Asepxia BB Liquid*[®] contributed to the increase in top line for the quarter. Key commercial innovation initiatives were implemented including point of sale marketing to attract more shoppers, increasing product visibility at more than 5,400 points of sale. All of these initiatives were supported by additional investments in TV and digital campaigns.

Fourth quarter EBITDA increased by Ps. 15.8 million, year on year, with a 17.6% margin. The 230 bps improvement in EBITDA margin is the result of a lower COGS base as part of fixed cost leverage effects from higher sales. This EBITDA growth was partially offset by one-time logistics expense associated with relocating Genomma's warehouse at the U.S. operation, in line with the Company's strategy to improve logistics and distribution efficiencies, as well as additional advertising and TV expenses, to increase brand recognition and visibility at new points of sale.

Latin America

Genomma's Central and South America operations achieved a double digit increase in sales when expressed in local currency when adopting IAS-29 & IAS-21, and 12.0% growth when expressed in Mexican pesos. This year-on-year increase in sales was driven by innovation initiatives, with particularly outstanding performance driven by key advertising campaigns during the quarter for *Teatrical*[®] in Argentina and Brazil, and *Cicatricure*[®] and *Asepxia*[®] throughout Latin America.

Brazil, Colombia and Central America had a very strong performance during the quarter. Go-to-market capabilities were also increased as the Company signed two major retailers in the region. On the other hand, net sales were negatively impacted



Innovation of Cicatricure[®] in Mexico



4Q-2018 innovation for US Market



by major currency translation effects in Argentina, which were partially offset from the application of hyperinflationary accounting following International Standard IAS-29, detailed on page 8.

Tío Nacho[®] continues to outperform across all regions

Successful execution of Cicatricure[®] in Brazil EBITDA margin for Genomma's Latin America operations decreased by 1.7 percentage points, year on year. The year on year margin contraction, reflects the sizeable impact of the currency translation of the Argentinean peso on overall operations, as well as stronger promotional and advertising campaigns including visibility programs at the point of sale. These effects were partially offset by the application of hyperinflationary accounting IAS-29.

It is important to note that in Argentina, during the year there was a lag effect between the Producer Price Index (IPP) and the Consumer Price Index (IPC), with the first one leading the second one until they eventually converge. During this period of mismatch COGS inflation accelerates faster than the consumer's purchasing power. In spite of this, Latin America reported a healthy 21.7% EBITDA margin for the quarter.



New Manufacturing Facility







Inside the Raw Materials Warehouse for OTC Production





Production area for OTC Solids Manufacturing Line.



https://inversionistas.genommalab.com

facility completed construction phase

• OTC manufacturing

KEY POINTS

 The OTC production layout includes capacity for:
Oalida

Solids Semi-solids Liquids Products

• Capacity of +1,500 storage locations at the OTC Raw Materials Warehouse



New Manufacturing Facility

KEY POINTS

 State-of-the-Art manufacturing equipment from Europe: Uhlmann Fette Norden Romaco Krones

 The first production line will manufacture solid OTC products

• The Finished Product Warehouse has a storage capacity of +50,000 storage locations.





OTC Plant Equipment









Quality Control Lab – OTC Plant



Progress on the Finished Product Warehouse (storage capacity of +50,000 positions)

https://inversionistas.genommalab.com



	FY 2017 As Reported	% Sales	FY 2018 As Reported	IAS 21 & 29	FY 2018 ⁽²⁾ Re-stated	% Sales
Net Sales	12,078.4	100.0%	12,281.8	(487.4)	11,794.4	100.0%
Gross Profit	8,121.3	67.2%	8,116.7	(352.0)	7,764.7	65.8%
Operating Income	2,531.4	21.0%	2,442.0	(140.9)	2,301.1	19.5%
EBITDA	2,600.3	21.5%	2,521.5	(143.1)	2,378.4	20.2%
Net Income	1,279.2	10.6%	1,217.7	(108.2)	1,109.5	9.4%

Consolidated Results for Full Year 2018

reached Ps. 11.79 billion

Full Year 2018 Net Sales

Full Year 2018 Net Sales reached Ps. 11.79 billion; a 2.4% year on year decrease. Sales during this year were driven by key trade initiatives implemented across the regions during 2018 to enhance point of sale execution and visibility, and by the impact from the Argentina subsidiary, due to the implementation of hyperinflation accounting described on page 8. These effects were offset by the major impact of currency translation also described on page 8.

Full Year 2018 EBITDA closed at Ps. 2.34 billion, as compared to Ps. 2.60 billion for the same period of 2017. Full Year 2018 EBITDA margin reached 20.2%; a 130bps year on year contraction. The EBITDA margin decrease was due to the major impact of currency translation from Latin America Operations, the Ps. 73.7 million in pre-operating expenses associated with the new manufacturing plant and to a lesser extent, to the investments made over the year on advertising and marketing strategies, as well as to the one-offs previously mentioned in the business review section. The negative impacts in the EBITDA margin were partially offset by the favorable impact from the Argentina subsidiary, due to the implementation of hyperinflation accounting described on page 8.

Consolidated Results for 4Q-2018


Fourth Quarter 2018 Net Sales reached Ps. 3.12 billion; an 8.3% year on year increase. This increase is primarily due to the execution of key initiatives at the point of sale throughout the different regions. Likewise, sales were impacted by currency and inflationary effects from the Argentina subsidiary, as previously described.

Fourth Quarter 2018 EBITDA closed at Ps. 580.7 million, as compared to Ps. 613.2 million for the same period of 2017. Fourth quarter 2018 EBITDA margin reached 18.6%; a 270 bps year on year contraction. The EBITDA margin decrease was mainly due to the previously mentioned net impact from hyperinflation and local currency depreciation in the Latin America region. To a lesser extent, the year on year negative impact in EBITDA is the result of additional trade and advertising investments made over the quarter, to support the beginning of the winter season, the Ps. 30.3 million in pre-operating expenses associated with the new manufacturing plant, and the one-offs previously described.



Alert[®] New Formula and Packaging





Genomma has been able to cope with major shocks in Argentina over the years

Adoption of IAS-29 (Hyperinflation Accounting in Argentina)

Following the categorization of Argentina as a country with a three-year cumulative inflation rate greater than 100%, the country is considered highly inflationary in accordance with IFRS. Consequently, the Company is reporting, starting from this 4Q-2018 results release, the operations of its subsidiary applying hyperinflation accounting.

The IFRS rules (IAS-29) requires to report the results of operations in hyperinflationary economies as if these were highly inflationary as of January 1, 2018, and to restate the year-to-date results for the change in the general purchasing power of the local currency, using official indices before converting the local amounts at the closing rate of the period.

Furthermore, IAS-29 requires the Company to restate the non-monetary assets and liabilities stated at historical cost on the balance sheet of operations in hyperinflation economies using inflation indices and to report the resulting hyperinflation through the income statement on a dedicated account for hyperinflation monetary adjustments in the finance line and report deferred taxes on such adjustments, when applicable.

At year-end 2018, the transition to hyperinflation accounting in accordance with the IFRS rules, resulted in Ps. 79.9 million monetary adjustment reported in the finance line of the Company's Statement of Comprehensive Income.

NOTE: Accounting standards recommend using the <u>**Consumer**</u> Price Index (IPC) as published by INDEC (Instituto Nacional de Estadística y Censos), to measure inflation. In 2018 general consumer prices increased by 47.6%.

Noteworthy is that the **<u>Producer</u>** Price Index (**IPP**) as published by INDEC increased 75.6% in general, and 101.9% for pharmaceutical products during 2018.

IPP is a leading indicator of *IPC*. When producers faced input inflation, (i.e. devaluation of the Argentinean Peso) those rising costs are eventually passed along to the retailers and in ultimately to the consumer. In this transition, there is a lag effect to consider.

Once 2018 Audit Results are completed, the Company will publish a reference base including the 2018 results per quarter as if we had reported under hyperinflation accounting since January 1, 2018.



Sales by Region* 4Q-2018 U.S.A 11% Mexico 38%

Latam 51%

Sales by Category & Region

(Figures in million Mexican Pesos)

	Over-tl	he-Counter (C	ОТС)	Pers	sonal Care (PC)			
	Q4-2017	Q4-2018	%Var	Q4-2017	Q4-2018	%Var	Q4-2017	Q4-2018	%Var
Mexico	719.4	761.8	5.9%	451.9	428.0	(5.3)%	1,171.3	1,189.7	1.6%
Latam	485.8	631.0	29.9%	946.3	980.7	3.6%	1,432.1	1,611.6	12.5%
U.S.	146.5	189.7	29.5%	135.3	145.4	7.5%	281.8	335.1	18.9%
Total	1,351.7	1,582.4	17.1%	1,533.5	1,554.1	1.3%	2,885.2	3,136.4	8.7%
		Over-the-Counter (OTC) Pe		sonal Care (PC)					
	Over-t	he-Counter (ОТС)	Per	sonal Care (PC)		Total	
	Over-t FY 2017	he-Counter (FY 2018	OTC) %Var	Per: FY 2017	sonal Care (FY 2018	PC) %Var	FY 2017	Total FY 2018	%Var
Mexico			,			,	FY 2017 4,770.4		<mark>%Var</mark> 2.9%
Mexico Latam	FY 2017	FY 2018	%Var	FY 2017	FY 2018	%Var		FY 2018	
	FY 2017 2,593.5	FY 2018 2,936.0	%Var 13.2%	FY 2017 2,176.9	FY 2018 1,971.5	%Var (9.4)%	4,770.4	FY 2018 4,907.5	2.9%

Results by Region

Mexico

Net Sales for the fourth quarter 2018 reached Ps. 1.19 billion; a 1.2% year on year increase. The Ps. 14.1 million increase is primarily due to the execution of winter season campaigns for the OTC category and to a lesser extent to a lower comparison base due to a black-out effect in sales faced at the end of 2017.

EBITDA for the quarter reached Ps. 173.9 million; a 14.7% margin reflecting a 4.0 percentage point year on year contraction. Fourth quarter 2018 EBITDA was impacted by Ps. 30.3 million in expenses associated with pre-production and pre-operating processes related to Genomma's new manufacturing facility, higher TV advertising & trade investments and to a lesser extent, to the one-off impact associated to the CEO transition.

U.S.

Fourth quarter 2018 Net Sales for Genomma's U.S. operations increased by 18.9%, to Ps. 335.1 million; a Ps. 53.3 million year on year increase. Expressed in U.S. dollars, top-line growth increased by 13.7%, year on year. This growth is mainly attributable to the different strategies implemented over the quarter focused on product innovation and point of sale execution.

Fourth quarter 2018 EBITDA amounted to Ps. 59.0 million. Fourth quarter 2018 EBITDA margin closed at 17.6%. The 2.3 percentage point expansion in margin as compared to the 15.3% EBITDA margin of the fourth quarter 2017 reflects a lower COGS base as part of fixed cost leverage effects from increased sales. This was partially offset by one-time logistics expenses and to a lesser extent, from higher advertising and TV expenses.

MEXICO Sales: Ps. 1.19 billion EBITDA Margin: 14.7%


U.S. Sales: Ps. 335.1 million EBITDA Margin: 17.6%

*Percentage of Consolidated Net Sales by Region as of Q4-2018.



LATIN AMERICA Sales: Ps. 1.60 billion EBITDA Margin: 21.7%

FX headwinds



Dec 2018

Jan 2018

Latin America

Fourth quarter 2018 Net Sales increased by 12.0% year on year, to Ps. 1.60 billion. The year on year growth in sales was the result of the favorable impact from the Argentina subsidiary, due to the implementation of hyperinflation accounting (IAS-29 & IAS-21) and to the product innovation and commercial initiatives implemented throughout the region. The increase in sales was partially offset by major impact from currency translation effect in the region.

EBITDA for the fourth quarter of 2018 reached Ps. 347.8 million, as compared to Ps. 350.6 million for the same period in 2017. The EBITDA margin for the quarter closed at 21.7%; a 2.8 percentage point decrease as compared to the 24.5% EBITDA margin in the fourth quarter of 2017. The margin contraction is the result of a major impact on the Argentina subsidiary due to currency translation effect and, to a lesser extent, to advertising and commercial initiatives that were implemented during the quarter and, one-off expenses related to regulatory processes. These effects were partially offset by the positive impact from the implementation of hyperinflation accounting in Argentina.

Other Income Statement Results for 4Q-2018

Gross Profit increased by 11.6% to Ps. 2.01 billion in the fourth quarter of 2018, compared to Ps. 1.80 billion during the fourth quarter of 2017. Fourth quarter 2018 Gross Margin increased by 190 bps, to close at 64.3%. Gross margin expansion for the quarter was primarily driven by a favorable sales mix and having a lower increase on COGS in comparison with the 8.3% increase on net sales year on year, resulting in an operational leverage effect. This was partially offset by the increase in some input costs associated with foreign exchange impact when consolidating the various currencies that depreciated during the quarter.

Selling, General, Marketing and Administrative Expenses, increased by 6.5 percentage points as a percentage of net sales, to 48.3%, compared to an SGM&A of 41.8% for the same quarter of 2017. The increased SGM&A is the result of a temporary boost in TV & advertising campaigns and additional execution of commercial visibility programs and to a lesser extent, to pre-operating expenses associated with the investments made for Genomma's new manufacturing facility and one-offs impacts previously described. These effects were additionally impacted by major currency devaluation in Argentina that affected the Latin America operations.

Comprehensive Financing Result represented Ps. 106.0 million cost in the fourth quarter of 2018, compared to a Ps. 16.7 million cost in the fourth quarter of 2017. The Ps. 89.4 million negative variation was a result of: i) a Ps. 93.9 million Foreign Exchange gain during Q4 2018, compared to a Ps. 115.7 million gain during Q4 2017;



ii) a Ps. 17.3 million increase in Financial Expenses to Ps. 161.4 million during Q4 2018, compared to Ps. 144.1 million during Q4 2017; iii) lower interest income amounting to Ps. 7.0 million during Q4 2018, compared to Ps. 11.7 million in Q4 2017; and to iv) a non-cash Ps. 45.5 million monetary loss resulting from applying hyperinflation accounting (IFRS IAS-29) in Argentina.

Income Tax Expense for the fourth quarter 2018 reported a Ps. 41.8 million increase, to close at Ps. 270.2 million as compared to the Ps. 228.4 million of the fourth quarter of 2017. The increase in income tax paid is the result of higher amounts of dividends repatriated from international operations, as well as impacts derived from inflationary accounting.

Net Income amounted to Ps. 205.8 million in the fourth guarter of 2018, compared to Ps. 338.6 million of net income of majority shareholders in the fourth guarter of 2017. The Ps. 132.8 million decrease in Net Income is due to the lower income before taxes on the fourth guarter of 2018 coupled with a higher effective tax rate reported in comparison to the same quarter of 2017.

Financial Position

Working Capital was optimized during the quarter and the cash conversion cycle was reduced from 97 days at the end December 2017 to 82 days at the end of December 2018:

- Accounts Receivable amounted to Ps. 2.92 billion as of December 31, 2018. • The days of consolidated accounts receivable amounted to 89; a one-day increase as compared to December 31, 2017.
- Inventories closed at Ps. 1.70 billion as of December 31, 2018. Days of Inventories amounted to 152; a 26-day increase guarter on guarter, that will be used to cover the incremental sales expected for Q1-2019.
- Trade Payables amounted to Ps. 1.77 billion as of December 31, 2018. As of the fourth guarter 2018, Days Payable Outstanding (DPO) closed at 159 days, from 100 days as of December 31, 2017. This temporary increase in DPO results from purchasing additional inventory to cover incremental sales expected for Q1-2019.

Fixed Assets. For the full year 2018, the Company invested Ps. 1.17 billion, primarily related to the construction of the Company's new manufacturing facility located in the State of Mexico.

Recoverable Taxes. The position is comprised of claims against the tax authorities relating mostly to VAT (IVA) and income taxes. The position increased by Ps. 201.7 million during 2018.

Net Financial Debt increased during the quarter due to the significant investments made into the new plant and the operation of the Company's share buyback program:

Days of Accounts Receivable (DSO) Q4'17 Q3'18 Q4'18 Mexico 107 99 105 35

LatAm	81	82	85
U.S.	74	56	51
Consolidated	90	86	89



Q4'17 Q1'18 Q2'18 Q3'18 Q4'18



- Cash and Equivalents amounted to Ps. 1.41 billion as of December 31, 2018, representing a 29.5% year on year increase; primarily due to an improved collection process.
- Gross Financial Debt amounted to Ps. 5.87 billion as of December 31, 2018, compared to Ps. 4.70 billion as of December 2017; a Ps. 1.17 billion increase derived from the proceeds partially obtained of a long-term loan with the IDB Invest and IFC associated with the investments in the new manufacturing facility.
- Net Financial Debt amounted to Ps. 4.46 billion; a Ps. 848.4 million increase as compared to December 31, 2017. The Company's long-term debt represented 88.5% of gross financial debt at the end of the fourth quarter 2018.

Share Buyback Program. During the three months ended on December 31, 2018, the Company operated its share buyback program, repurchasing 1,000,000 shares representing a total investment of Ps. 12.8 million.

Free Cash Flow from Operations. Genomma generated Ps. 145.0 million during the twelve months of 2018. Excluding investments made in the Company's new manufacturing facility and brands acquisition, free cash flow would have reached Ps. 1.37 billion for 2018.

Key Financial Metrics

	Q4-2018
EBITDA / Interest Paid	4.29x
Net Debt / EBITDA	1.87x
Shares Outstanding (as of January 31, 2019)*	1,048,000,000

* In compliance with the resolutions of the Annual General Shareholder's Meeting, dated April 18, 2018, 733,370 buyback shares were effectively canceled, with INDEVAL, on January 31, 2019.

8,916,900 shares re-purchased in the twelve months of 2018, for a total investment of Ps. 134.0 million



CONFERENCE CALL Q4-2018

Wednesday, February 27 2018 at 12:00 p.m. ET / 11:00 a.m. CST

> Led by: Jorge Luis Brake CEO

Antonio Zamora CFO

Enrique González IRO

Webcast: 4Q-2018 Earnings Call

To participate, please dial-in:

United States: +1 877-407-8031

International: +1 201-689-8031

Q4-2018 Other Relevant Corporate Events

 <u>Cancellation of Shares</u> – In compliance with the resolutions of the Annual General Shareholder's Meeting, dated April 18, 2018, 733,370 buyback shares were effectively canceled, with INDEVAL, on January 31, 2019.

Sell-side Analyst Coverage

As of the end of December, 2018 LAB B is covered by 14 sell-side analysts at the following brokerages: Casa de Bolsa Credit Suisse; Banco Itaú BBA; Santander Investment Securities; BBVA Bancomer.; UBS Casa de Bolsa; JP Morgan Securities; Vector Casa de Bolsa; Barclays Bank; BTG Pactual US Capital; GBM Grupo Bursátil Mexicano.; Grupo Financiero Banorte; HSBC Securities (USA); Bradesco BBI and Actinver Casa de Bolsa, S.A. de C.V.

About Genomma

Genomma Lab Internacional, S.A.B. de C.V. is one of the leading pharmaceutical and personal care products companies in Mexico with an increasing international presence. Genomma Lab develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. Genomma Lab relies on the combination of a successful new product development process, a consumer-oriented marketing, a broad retail distribution network and a low-cost, highly flexible operating model.

Genomma Lab's shares are listed on the Mexican Stock Exchange under the ticker: "LAB B" (Bloomberg: LABB:MM).









Note on Forward-Looking Statements

This report may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like "believe," "anticipate," "expect," "envisages," "will likely result," or any other words or phrases of similar meaning. Such statements are subject to a number of risks, uncertainties and assumptions. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this presentation and in oral statements made by authorized officers of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information:

Enrique González, Head of IR Tel: +52 (55) 5081-0075

inversion@genommalab.com

Barbara Cano, InspIR Group Tel: +1 (646) 452-2334 barbara@inspirgroup.com



GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V. AND SUBSIDIARIES

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

For the three and twelve months ended December 31, 2018 and 2017

Thousands of Mexican pesos		FOURTH C	UARTER			A	CUMULAT	ED		
	2018	%Sales	2017	%Sales	Var %	2018	%Sales	2017	%Sales	Var %
Net Sales	3,124,066	100.0%	2,885,210	100.0%	8.3%	11,794,419	100.0%	12,078,443	100.0%	(2.4)%
Cost of goods sold	1,116,775	35.7%	1,087,176	37.7%	2.7%	4,029,685	34.2%	3,957,129	32.8%	1.8%
Gross Profit	2,007,291	64.3%	1,798,034	62.3%	11.6%	7,764,734	65.8%	8,121,314	67.2%	(4.4)%
Selling, general and administrative expenses	1,509,617	48.3%	1,206,802	41.8%	25.1%	5,500,596	46.6%	5,553,592	46.0%	(1.0)%
Other (income) expense	(83,036)	(2.7)%	(21,920)	(0.8)%	278.8%	(114,217)	(1.0)%	(32,533)	(0.3)%	251.1%
EBITDA	580,710	18.6%	613,152	21.3%	(5.3)%	2,378,355	20.2%	2,600,255	21.5%	(8.5)%
Depreciation and amortization	28,720	0.9%	17,270	0.6%	66.3%	77,259	0.7%	68,884	0.6%	12.2%
Income from operations	551,990	17.7%	595,882	20.7%	(7.4)%	2,301,096	19.5%	2,531,371	21.0%	(9.1)%
Interest expense	(161,405)	(5.2)%	(144,062)	(5.0)%	12.0%	(554,634)	(4.7)%	(483,519)	(4.0)%	14.7%
Interest income	6,954	0.2%	11,715	0.4%	(40.6)%	31,769	0.3%	40,085	0.3%	(20.7)%
Foreign exchange result	93,918	3.0%	115,696	4.0%	(18.8)%	901	0.0%	24,922	0.2%	(96.4)%
Inflationary result from monetary position	(45,485)	(1.5)%	-	0.0%		(79,854)	(0.7)%	-	0.0%	
Comprehensive financing income (cost)	(106,018)	(3.4)%	(16,651)	(0.6)%	536.7%	(601,818)	(5.1)%	(418,512)	(3.5)%	43.8%
Associated company	29,988	1.0%	35,307	1.2%	(15.1)%	64,162	0.5%	52,325	0.4%	22.6%
Income before income taxes	475,960	15.2%	614,538	21.3%	(22.5)%	1,763,440	15.0%	2,165,184	17.9%	(18.6)%
Income tax expense	270,162	8.6%	228,375	7.9%	18.3%	653,975	5.5%	758,696	6.3%	(13.8)%
Consolidated net income	205,798	6.6%	386,163	13.4%	(46.7)%	1,109,465	9.4%	1,406,488	11.6%	(21.1)%
Net income of minority stockholders	-	0.0%	47,528	1.6%	(100.0)%	-	0.0%	127,282	1.1%	(100.0)%
Net income of majority stockholders	205,798	6.6%	338,635	11.7%	(39.2)%	1,109,465	9.4%	1,279,206	10.6%	(13.3)%



GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V. AND SUBSIDIARIES CONSOLIDATED STATEMENT OF FINANCIAL POSITION

		of	As of	
Thousands of Mexican pesos		ber 31,	September 30	
400550	2018	2017	2018	
ASSETS				
CURRENT ASSETS	4 44 4 6 44	1 000 711	4 4 0 0 0 0 0	
Cash and equivalents and restricted fund Clients - Net	1,414,641	1,092,741	1,128,902	
	2,923,135	2,745,173	2,765,642	
Recoverable Taxes	1,587,097	1,385,360	1,502,147	
Other accounts receivable*	808,944	875,085	997,597	
Inventory - Net	1,697,032	1,264,211	1,398,609	
Prepaid expenses	566,715	478,069	843,612	
Total current assets	8,997,564	7,840,639	8,636,509	
Non-current assets				
Trademarks	4,858,774	5,149,632	4,842,727	
Investment in shares	1,555,834	1,472,805	1,525,846	
Building, properties and equipment – Net	1,870,234	548,649	1,138,436	
Deferred income tax, assets and others	794,851	873,981	711,798	
Total non-current assets	9,079,693	8,045,067	8,218,807	
TOTAL ASSETS	18,077,257	15,885,706	16,855,316	
LIABILITIES AND STOCKHOLDERS' EQUITY				
Current Liabilities				
Current portion of long-term debt	676,022	3,013,055	85,428	
Suppliers	1,774,441	1,098,471	1,535,350	
Other current liabilities	1,866,678	1,857,124	1,714,834	
Income tax payable	168,177	336,373	262,948	
Total current liabilities	4,485,318	6,305,023	3,598,560	
Non-current liabilities				
Long-term debt securities	3,928,961	1,500,000	3,926,479	
Long-term loans with financial institutions	1,268,389	190,054	1,287,395	
Deferred income tax and other long term liabilities	166,770	41,962	158,785	
Payable dividends to shareholders	800,000	800,000	800,000	
Total liabilities	10,649,438	8,837,039	9,771,219	
Stockholders' equity				
Contributed Capital	1,914,306	1,914,306	1,914,306	
Retained earnings	6,806,180	5,993,327	6,280,648	
Cumulative translation effects of foreign subsidiaries	27,606	332,609	196,623	
Repurchased shares - Net	(1,320,273)	(1,393,476)	(1,307,480	
Minority interest	-	201,901	-	
Total stockholders' equity	7,427,819	7,048,667	7,084,097	
TOTAL EQUITY AND LIABILITIES	18,077,257	15,885,706	16,855,316	
· · · · · · · · · · · · · · · · · · ·	. ,			



GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V. AND SUBSIDIARIES

CONSOLIDATED STATEMENT OF CASH FLOWS

For the three and twelve months ended December 31, 2018

Thousands of Mexican pesos	4Q-2018	2018
Cash and cash equivalents beginning of period	1,128,902	1,092,741
Consolidated Net Income	205,798	1,109,465
Charges to results with no cash flow:		
Depreciation and amortization	30,419	81,164
Income tax	270,161	653,975
Accrued interest and others	192,412	567,631
—	762,290	2,475,735
Changes in Working Capital:		
Clients - Net	(157,493)	(177,963)
Inventories	(298,338)	(411,874)
Suppliers	239,091	675,970
Other current assets	150,873	(125,295)
Paid income tax	(201,675)	(664,294)
Other current liabilities	159,328	171,660
	(193,163)	(913,256)
	• • •	
Net cash generated (used) in operating activities	569,127	1,562,479
Investing activities:		
Investment in fixed assets	(846,765)	(1,429,823)
Sales of equipment	2,372	6,269
Brand acquisitions and others	1,634	(77,161)
Net cash outflow on acquisitions subsidiary	-	(18,867)
Net cash outflow on sale of subsidiary	30,747	126,210
Interest collected	31,769	31,769
Other asset acquisitions	33,468	(55,905)
Net cash generated (used) in investing activities	(746,775)	(1,417,508)
Financing activities:		
Payments of borrowings with financial institutions	(19,006)	(3,766,022)
Loans with financial and securities institutions	600,000	4,927,490
Interest paid	(213,049)	(554,634)
Stock repurchase	(12,794)	(133,932)
Net cash used in financing activities	355,151	472,902
Net increase in cash and cash equivalents before foreign exchange		
adjustments coming from international operations and inflationary		
affects cash	177,503	617,873
Foreign exchange and inflationary effects from international	-	-
operations	108,236	(295,973)
Accumulated cash flow at the end of the period	1,414,641	1,414,641
Less - restricted fund	23,269	23,269
Cash and cash equivalents at end of period balance for operation	1,391,372	1,391,372
	.,	.,

https://inversionistas.genommalab.com